Business activities in the health and pharmaceutical industry slumped in China in 2019 after a robust performance in the previous few years. The value of outbound investment deals conducted by financial buyers in the pharmaceutical sector from mainland China amounted to around 536 million U.S. dollars in 2019, falling from around 3.2 billion in the previous year.
Value of outbound investment deals in the pharmaceutical sector from mainland China between 2016 and 2019, by funding method
(in million U.S. dollars)
Characteristic
State owned enterprises (SOE)
Privately owned enterprises (POE)
Financial buyers
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Exclusive Premium Statistic
To access all Premium Statistics, you need a paid Statista Account
The deal value figures refer only to the deals whereby a value has been disclosed (referred to in this presentation as “disclosed value”)
Outbound deals refer to mainland China company acquisitions abroad.
Financial buyer refers to investors that acquire companies with the objective of realizing a return on their investment by selling the business as a profit at a future date and mainly, but not entirely, comprise private equity (PE) and venture capital (VC) funds.
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how Statista can support your business.
PwC. (April 15, 2020). Value of outbound investment deals in the pharmaceutical sector from mainland China between 2016 and 2019, by funding method (in million U.S. dollars) [Graph]. In Statista. Retrieved September 01, 2024, from https://www.statista.com/statistics/1112615/china-pharmaceutical-outbound-deal-value-by-funding-method/
PwC. "Value of outbound investment deals in the pharmaceutical sector from mainland China between 2016 and 2019, by funding method (in million U.S. dollars)." Chart. April 15, 2020. Statista. Accessed September 01, 2024. https://www.statista.com/statistics/1112615/china-pharmaceutical-outbound-deal-value-by-funding-method/
PwC. (2020). Value of outbound investment deals in the pharmaceutical sector from mainland China between 2016 and 2019, by funding method (in million U.S. dollars). Statista. Statista Inc.. Accessed: September 01, 2024. https://www.statista.com/statistics/1112615/china-pharmaceutical-outbound-deal-value-by-funding-method/
PwC. "Value of Outbound Investment Deals in The Pharmaceutical Sector from Mainland China between 2016 and 2019, by Funding Method (in Million U.S. Dollars)." Statista, Statista Inc., 15 Apr 2020, https://www.statista.com/statistics/1112615/china-pharmaceutical-outbound-deal-value-by-funding-method/
PwC, Value of outbound investment deals in the pharmaceutical sector from mainland China between 2016 and 2019, by funding method (in million U.S. dollars) Statista, https://www.statista.com/statistics/1112615/china-pharmaceutical-outbound-deal-value-by-funding-method/ (last visited September 01, 2024)
Value of outbound investment deals in the pharmaceutical sector from mainland China between 2016 and 2019, by funding method (in million U.S. dollars) [Graph], PwC, April 15, 2020. [Online]. Available: https://www.statista.com/statistics/1112615/china-pharmaceutical-outbound-deal-value-by-funding-method/